Corporate news

Revenues +11.6%, Adjusted EBITDA +13.1%Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3%Q1…

Organic growth: revenue +2.9%, adjusted EBITDA +4.1%Destocking in vial business partially offset by strong growth in medical devicesGrowth strategy…

Exchange with Gerresheimer management at the Düsseldorf headquartersGerresheimer produces medical systems such as inhalers and auto-injectors in…

Innovative combination product of furosemide and on-body deviceReady-to-market device designed, developed and manufactured by GerresheimerPatented…

Complementary product portfolio and broad footprint of production sites in EuropeStrengthening the market position as a full-service provider for the…

Expansion of the site in the Republic of North Macedonia with a new production hall for glass syringesTotal investment volume of over EUR 100 millionA…

2.3 MWp rooftop photovoltaic system on production buildingGerresheimer increases share of green electricity in its energy supplyGoal for 2030: 100%…

Organic growth Q3 2024 (9M 2024): Revenue +2.6% (9M 2024: 2.0%), Adjusted EBITDA +3.5% (9M 2024: 3.1%)Plastics & Devices grows organically by +9.2%…

Market advances adoption of ready-to-use containersImproved operational efficiency in pharmaceutical manufacturing processesIncreased patient safety…